INOTERSEN IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY AND CARDIOMYOPATHY: RESULTS OF THE PHASE 3 STUDY NEURO-TTR
Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Merrill D. Benson(Indiana University School of Medicine), Carol Whelan(The Royal Free Hospital), Brian Drachman(Penn Presbyterian Medical Center), Spencer Guthrie(Heidelberg University), Elizabeth J. Ackermann(Université Paris-Sud), Steve Hughes(Ionis Pharmaceuticals (United States)), Stephen B. Heitner(Brigham and Women's Hospital), Li Tai(Ionis Pharmaceuticals (United States)), Brett P. Monia(Ionis Pharmaceuticals (United States))
Cited by 6
Related Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k